RxDoctor Payments DataLook up a doctor →

Sara Beeler, APRN

Oncology · Tampa, FLNPI 1720328198

Payments from drug & device makers

$337,478in general payments, 2019–2025

Across 1,343 payments — averaging $251.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$266K
  • Daiichi Sankyo Inc.$55K
  • Novartis$3K
  • Gilead$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $11K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)439$266,246
Daiichi Sankyo Inc.100$54,568
Novartis106$2,654
Gilead(2 entities)57$1,130
Johnson & Johnson60$1,077
E.r. Squibb & Sons, L.L.C.60$1,039
Bristol Myers Squibb44$896
Pfizer40$797
Incyte Corporation34$684
Merck34$664
Lilly USA, LLC29$495
AbbVie18$469
Eisai Inc.20$367
GSK16$353
Regeneron Healthcare Solutions, Inc.14$346
Astellas Pharma US Inc16$331
Puma Biotechnology, Inc.17$316
Seagen Inc.17$296
Bayer15$294
Sanofi14$277
Amgen15$277
Takeda Pharmaceuticals U.S.A., Inc.9$273
Tersera Therapeutics LLC9$249
Pharmacyclics LLC, An Abbvie Company10$237
Beigene USA, Inc.6$152
Exelixis Inc.5$147
Deciphera Pharmaceuticals Inc.7$146
Sumitomo Pharma America, Inc.8$136
Stemline Therapeutics Inc.6$129
Dendreon Pharmaceuticals LLC4$129
Taiho Oncology, Inc.7$118
Pharmaessentia USA Corporation5$118
Rigel Pharmaceuticals, Inc.4$113
Legend Biotech USA Inc.4$111
Karyopharm Therapeutics Inc.6$108
Genentech USA, Inc.6$104
Pharmacosmos Therapeutics Inc.5$98
AVEO Pharmaceuticals, Inc.5$98
Mirati Therapeutics, Inc.4$92
EMD Serono, Inc.4$88
Genmab U.S., Inc.4$85
Sobi, Inc5$79
Ipsen Biopharmaceuticals, Inc4$78
Jazz Pharmaceuticals Inc.4$76
Blueprint Medicines Corporation3$67
Boston Scientific3$65
Geron Corporation3$63
Array Biopharma Inc3$59
Myriad Genetic Laboratories, Inc.2$52
CTI Biopharma Corp.3$42
Agios Pharmaceuticals, Inc.2$38
GE HealthCare2$36
G1 Therapeutics, Inc.2$36
CSL Behring2$36
ADC Therapeutics America, Inc.1$33
Myovant Sciences Inc.2$32
Recordati_rare_diseases_inc.2$30
Immunocore Limited1$29
Boehringer Ingelheim1$29
TG Therapeutics, Inc.1$29

How this compares

$337,478 in reported general payments places this provider in the 95th percentile of 24 oncology providers in Florida.

See all oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$36,302
Medicare patients
33
Services billed
2,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other oncology in Tampa

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →